Just completed the acquisition of the ophthalmology channel business Zhuhai Xiangle, Guanxi Bio has been aiming at the pharmaceutical enterprises without stopping. The company plans to acquire the production and sales of antibiotics oxycephalosporin, Huidisen, by raising the raised funds of 1.8 billion yuan. The bill passed the resolution of the company's general meeting of shareholders on November 10th.
Zhu Weiping, chairman of the company, said: "The acquisition of Huidison can not only improve the company's profitability, but more importantly, he is the stepping stone for the company to achieve the established strategy of entering the pharmaceutical industry." On the one hand, Huidison's good cash flow and profitability can lay a solid capital foundation for the company's strategic expansion; on the other hand, its strong marketing capabilities can plug in the engine for the company's future promotion of new drugs.
In 2015, Guanxi Biotech proposed to form a “3+1†core business structure, namely, three major business segments of materials, cells and pharmaceuticals and a technology incubation platform. Previously, the company has already laid out its layout in areas such as recycled materials, cell stem cells, and technology incubation. Now, through the acquisition of Huidison, the pharmaceutical sector will be opened.
Huidison's two-year profit has tenfold
In 2013, Wang Chao team purchased the entire shareholding of Huidison from the original shareholder. In two years, the only product of Huidison was oxycephalosporin, which achieved a net profit of less than 7 million from 80 million.
Data show that in 2014, 2015 and the first half of 2016, Huidison achieved a net profit of 6,796,800 yuan, 80,880,600 yuan, and 73,890,300 yuan respectively. Wang Chao promised that the net profit realized by Huidison in 2015-2017 will be no less than RMB 0.8 billion, RMB 120 million and RMB 160 million respectively.
However, in the context of the country's strong "limitation of resistance", Huidison's continued profitability is questioned. In this regard, Wang Chao said that in fact, the sharp increase in the performance of Huidison is also the beginning of the country began to rectify antibiotic abuse in 2013. Huidison can stand out from the crowd, mainly because it has many exclusive advantages.
Compared with the general antibiotics, the toxic side effects of oxycephalosporin are small, and the applicable strains are wide. Compared with the products of similar indications, the cost is low. In the context of limiting resistance, the advantages of famous products are more prominent. In the future, the target market for Huidison's oxycephalosporin is the broader third- and fourth-line primary medical market, and the team is also striving to include it in the base drug range.
Thousands of horses still need Bole, trapped in the inflexibility of the original system and other factors, Huidison's early sales have been sluggish until Wang Chao, who has been working in the medical field for more than 20 years. In terms of marketing, after Wang Chao entered the company, he led the team to implement the academic promotion model of foreign pharmaceutical companies in the field of anti-infection.
Medical Equipment Disposal,Syringes Needles Sizes,Disposable Syringe,Insulin Syringe
FOSHAN PHARMA CO., LTD. , https://www.fospharma.com